Bone marrow-derived mesenchymal stem cells: a potential therapy in an autoimmune hepatitis rat model
Abstract
Background: Autoimmune hepatitis (AIH) is becoming more common worldwide. The therapy choices for AIH are still limited, with unfavorable side effects resulting in patients with a low quality of life. This study aims to study the therapeutic role of bone marrow-derived mesenchymal stem cells (MSCs) on AIH in the rat model.
Methods: Twenty-nine white Wistar rats were used for a total of 53 days. Four groups were set up; Group I (5 rats) was used as the negative control (CON). Group II (24 rats) was administered Concanavalin A (Con A) 20 mg/kg ip once a week for five consecutive weeks. Sixteen rats from group II were divided among groups III and IV after stoppage of Con A and injected with 2 x106 BM-MSCs via tail vein. Group III (TTT-12) rats were sacrificed after 12 days and Group IV (TTT-18) after 18 days. Morphological, biochemical, histopathological, and immunohistochemical studies were conducted.
Results: The administration of BM-MSCs lowered elevated serum levels of AST by 47% after 12 days and 19% after 18 days whereas the level of ALT decreased by 13% and 20.8%in group Con A. Serum inflammatory cytokines IL-10 and tumor necrosis factor alpha (TNF-α) increased in the Con A group were decreased in treated groups by 27% and 23% in TTT-12 and 22.8% and 1.8% in TTT-18. In group TTT-12, the area of Kupffer cells immunostained with CD68 was significantly reduced by 72%, whereas the BM-MSCs immunostained with CD44 were more intense by increasing by 257%. The therapeutic effect of BM-MSCs in group TTT-12 exceeded that in TTT-18 decreasing liver enzymes, inflammation and fibrosis, and restoring liver structure.
Conclusions: BM-MSCs achieved a considerable short-term improvement in the AIH model; however, repeated injections were necessary to achieve a sustained therapeutic effect.
Keywords: Liver; Autoimmunity; MSCs; Inflammatory cytokines; CD68; CD44; Histopathology
Full Text:
PDFReferences
Grønbæk L, Vilstrup H, Jepsen P. Autoimmune hepatitis in Denmark: Incidence, prevalence, prognosis, and causes of death. A nationwide registry-based Cohort Study. Journal of Hepatology, (2014); 60(3): 612–617.
Lamba M, Ngu J, Stedman C. Trends in Incidence of Autoimmune Liver Diseases and Increasing Incidence of Autoimmune Hepatitis. Clinical Gastroenterology and Hepatology, (2021); 19(3): 573-579.
Vuerich M, Wang N, Kalbasi A, Graham J, Longhi MS. Dysfunctional Immune Regulation in Autoimmune Hepatitis: From Pathogenesis to Novel Therapies. Frontiers in Immunology, (2021); 12: 76436
Kumar BG, Sethy PC, Gupta RA. Rare etiology of persistent jaundice in type 1 autoimmune hepatitis. Archive of Clinical Cases, (2021); 8(3): 37–41.
Manns MP, Czaja AJ, Gorham JD, Krawitt EL, Mieli-Vergani G, Vergani D, et al. Diagnosis and management of autoimmune hepatitis. Hepatology, (2010); 51(6): 2193–2213.
Czaja AJ, Freese DK. Diagnosis and treatment of autoimmune hepatitis, Hepatology, (2002); 36(2): 479–497.
Vierling JM. Autoimmune hepatitis and overlap syndromes: Diagnosis and management, Clinical Gastroenterology and Hepatology, (2015); 13(12): 2088–2108.
Liwinski T, Heinemann M, Schramm C. Semin The intestinal and biliary microbiome in autoimmune liver disease-current evidence and concepts. Immunopathology. (2022); 44(4): 485–507.
Gatselis NK, Zachou K, Koukoulis GK, Dalekos GN. Autoimmune hepatitis, one disease with many faces: etiopathogenetic, clinico-laboratory and histological characteristics. World journal of gastroenterology, (2015); 21(1): 60.
Mieli-Vergani G, Vergani D, Czaja AJ, Manns MP, Krawitt EL, et al. Montano-Loza AJ. Autoimmune hepatitis. Nature Reviews Disease Primers, (2018); 4(1): 1-21.
Ferri S, Muratori L, Lenzi M, Granito A, Bianchi FB, Vergani D. HCV and autoimmunity. Current pharmaceutical design, (2008); 14(17): 1678-1685.
Löhr H, Treichel U, Poralla T, Manns M, zum Büschenfelde KM, Fleischer B. Liver-infiltrating T helper cells in autoimmune chronic active hepatitis stimulate the production of autoantibodies against the human asialoglycoprotein receptor in vitro. Clinical & Experimental Immunology, (1992); 88(1): 45-9.
Ichiki Y, Aoki CA, Bowlus CL, Shimoda S, Ishibashi H, Gershwin ME. T cell immunity in autoimmune hepatitis Autoimmunity Reviews, (2005); 4(5): 315–321.
Galderisi U, Peluso G, Di Bernardo G. Clinical trials based on mesenchymal stromal cells are exponentially increasing: where are we in recent years? Stem cell reviews and reports, (2022); 18(1): 23-36.
Liberal R, Diego V, Giorgina M. Update on Autoimmune Hepatitis. Journal of Clinical and Translational Hepatology, (2015); 3(1): 42–52.
Wong LL, Fisher HF, Stocken DD, Rice S, Khanna A, Heneghan MA, et al. The Impact of Autoimmune Hepatitis and Its Treatment on Health Utility. Hepatology, (2018); 68(4): 1487–1497.
De Luca-Johnson J, Wangensteen K J, Hanson J, Krawitt E, Wilcox R. Natural History of Patients Presenting with Autoimmune Hepatitis and Coincident Nonalcoholic Fatty Liver Disease. Digestive Diseases and Sciences, (2016); 61(9): 2710–2720.
Zhou YK, Zhu LS, Huang HM, Cui SJ, Zhang T, et al. Stem cells from human exfoliated deciduous teeth ameliorate concanavalin A-induced autoimmune hepatitis by protecting hepatocytes from apoptosis. World Journal of Stem Cells, (2020); 12(12): 1623.
Hoang DM, Pham PT, Bach TQ, Ngo AT, Nguyen QT, et al. Stem cell-based therapy for human diseases. Signal Transduction and Targeted Therapy; Springer Nature, (2022); 7(1):1-41.
Yang X, Meng Y, Han Z, Ye F, Wei L, Zong C. Mesenchymal stem cell therapy for liver disease: full of chances and challenges. Cell & Bioscience, (2020); 10(10):1-8.
Maleki M, Ghanbarvand F, Behvarz M R, Ejtemaei M, Ghadirkhomi E. Comparison of Mesenchymal Stem Cell Markers in Multiple Human Adult Stem Cells. International Journal of Stem Cells, (2014); 7(2): 118–126.
Kolf CM, Cho E, Tuan RS. Mesenchymal stromal cells. Biology of adult mesenchymal stem cells: regulation of niche, selfrenewal, and differentiation. Arthritis Research and Therapy, (2007); 9: 1-10.
de Souza Fernandez T, de Souza Fernandez C. Mesenchymal stem cells: biological characteristics and potential clinical applications for haematopoietic stem cell transplantation. IntechOpen, (2016) Jul 20.Transplantation. InTech eBooks, 2016; URL: https://doi.org/10.5772/63772
Ramos LT, Sánchez-Abarca L I, Muntión S, Preciado S, Puig N, et al. MSC surface markers (CD44, CD73, and CD90) can identify human MSC-derived extracellular vesicles by conventional flow cytometry. Cell Communication and Signaling, (2016); 14(14): 1-4
Szabo´ GV, Ko¨vesd Z, Cserepes J, Daro´czy J, Belkin M, Acsa´dy G. Peripheral blood-derived autologous stem cell therapy for the treatment of patients with late-stage peripheral artery disease-results of the short- and long-term follow-up. Cytotherapy, (2013); 15(10):1245–1252.
Wang LT, Ting CH, Yen ML, Liu KJ, Sytwu HK, Wu KK, Yen BL. Human mesenchymal stem cells (MSCs) for treatment towards immune- and inflammation-mediated diseases: review of current clinical trias. J Biomed Sci, (2016); 23(1):76–89.
He C, Yang Y, Zheng K, Chen Y, Liu S, et al. Mesenchymal stem cell-based treatment in autoimmune liver diseases: underlying roles, advantages and challenges. Therapeutic Advances in Chronic Disease, (2021); 12: 1-18.
Wang HX, Liu M, Weng SY, Li JJ, Xie C, et al. Immune mechanisms of Concanavalin A model of autoimmune hepatitis. World journal of gastroenterology, (2012); 18(2): 119.
Zhang X, Wei HX, Rui S, Wei H, Tian Z. Opposite effects of high and low doses of interleukin-2 on T cell-mediated hepatitis in mice (interleukin-2 on hepatitis). Hepatology International, (2010); 4: 641-648
Ye, T, Wang T, Yang X, Fan X, Wen M, Shen Y, Xi X, Men R, Yang L. Comparison of Concanavalin a-Induced Murine Autoimmune Hepatitis Models. Cellular Physiology and Biochemistry, (2018); 46(3): 1241-1251.
Louis H, Le Moine A, Quertinmont E, Peny MO, Geerts A, Goldman M, Le Moine O, Devière J. Repeated concanavalin a challenge in mice induces an interleukin 10-producing phenotype and liver fibrosis. Hepatology, (2000); 31(2): 381–390.
Bos C, Delmas Y, Desmoulière A, Solanilla A, Hauger O, et al. In Vivo MR Imaging of Intravascularly Injected Magnetically Labeled Mesenchymal Stem Cells in Rat Kidney and Liver. Radiology, (2004); 233(3): 781–789.
Kim M D, Kim SS, Cha HY, Jang SH, Chang DY, et al. Therapeutic effect of hepatocyte growth factor-secreting mesenchymal stem cells in a rat model of liver fibrosis. Experimental & Molecular Medicine, (2014); 46(8): e110.
Cho K, Woo S, Seoh J, Han H, Ryu K. ‘Mesenchymal stem cells restore CCL4-induced liver injury by an antioxidative process’, Cell Biology International, (2012); 36(12): 1267–1274.
Soleimani M, Nadri S. A protocol for isolation and culture of mesenchymal stem cells from mouse bone marrow, Nature Protocols. (2009); 4(1): 102–106,
Kocabiyik B, Gumus E, Abas BI, Anik A, Cevik O. Human wharton-jelly mesenchymal stromal cells reversed apoptosis and prevented multi-organ damage in a newborn model of experimental asphyxia. Journal of Obstetrics and Gynaecology, (2022); 42(8):3568-3576.
Maridas DE, Rendina-Ruedy E, Le PT, Rosen CJ. Isolation, culture, and differentiation of bone marrow stromal cells and osteoclast progenitors from mice. Journal of Visualized Experiments, (2018); 131: e56750.
Handke M, Rakow A, Singer D, Miebach L, Schulze F, et al. Bone marrow from periacetabular osteotomies as a novel source for human mesenchymal stromal cells. Stem Cell Research & Therapy, (2023); 14(1): 315.
Itoh A, Isoda K, Kondoh M, Kawase M, Kobayashi M, et al. Hepatoprotective Effect of Syringic Acid and Vanillic Acid on Concanavalin A-Induced Liver Injury. Biological and Pharmaceutical Bulletin, (2009); 32(7): 1215–1219.
Chen Y, Chen S, Liu LY, Zou ZL, Cai YJ, et al. Mesenchymal stem cells ameliorate experimental autoimmune hepatitis by activation of the programmed death 1 pathway. Immunology Letters, (2014); 162(12): 222–228.
Zatroch KK, Knight CG, Reimer JN, Pang DSJ. Refinement of intraperitoneal injection of sodium pentobarbital for euthanasia in laboratory rats (Rattus norvegicus). BMC Veterinary Research, (2016); 13:1-7.
Chu T, Chan H, Hu T, Wang E, Ma Y, et al. Celecoxib enhances the therapeutic efficacy of epirubicin for Novikoff hepatoma in rats. Cancer Medicine, (2018); 7(6): 2567–2580.
Charan J, Kantharia N. How to calculate sample size in animal studies? Journal of Pharmacology and Pharmacotherapeutics, (2013); 4(4): 303-6.
Bozward AG, Ronca V, Osei-Bordom D, Oo YH. Gut-liver immune traffic: deciphering immune-pathogenesis to underpin translational therapy. Front Immunol, (2021); 12: 1–12
Richardson N, Wootton GE, Bozward AG, Oo YH. Challenges and opportunities in achieving effective regulatory T cell therapy in autoimmune liver disease. Seminars in Immunopathology, (2022); 44(4): 461–474.
Sirbe C, Simu G, Szabo I, Grama A, Pop TL. Pathogenesis of Autoimmune Hepatitis—Cellular and Molecular Mechanisms. International Journal of Molecular Sciences, (2021); 22(24): 13578.
Balitzer D, Shafizadeh N, Peters MG, Ferrell LD, Alshak N, Kakar S. Autoimmune hepatitis: review of histologic features included in the simplified criteria proposed by the international autoimmune hepatitis group and proposal for new histologic criteria. Modern Pathology, (2017); 30(5): 773–783.
Heneghan MA, McFarlane IG. Current and novel immunosuppressive therapy for autoimmune hepatitis. Hepatology, (2002); 35(1): 7–13.
Ruiz, R, Kirk, AD. Long-Term Toxicity of Immunosuppressive Therapy. Transplantation of the liver 3rd ed. (2105); 1354-1363. Elsevier eBooks. URL: https://doi.org/10.1016/b978-1-4557-0268-8.00097-x
Salehinejad P, Moshrefi M, Eslaminejad T. An overview on mesenchymal stem cells derived from extraembryonic tissues: Supplement sources and isolation methods. Stem Cells and Cloning: Advances and Applications, (2020); 13: 57–65.
Oh SY, Choi YM, Kim HY, Park YS, Jung SC, et al. Application of Tonsil-Derived Mesenchymal Stem Cells in Tissue Regeneration: Concise Review. Stem Cells, (2019); 37(10): 1252–1260.
Gopalarethinam J, Nair AP, Iyer M, Vellingiri B, Subramaniam MD. Advantages of mesenchymal stem cell over the other stem cells. Acta Histochemica, (2023); 125(4): 52041.
Yamaguchi T, Sato H, Kato-Itoh M, Goto T, Hara H, et al. Interspecies organogenesis generates autologous functional islets. Nature, (2017); 542(7640): 191–196.
Inoue Y, Iriyama A, Ueno S, Takahashi H, Kondo M, et al. Subretinal transplantation of bone marrow mesenchymal stem cells delays retinal degeneration in the RCS rat model of retinal degeneration. Experimental Eye Research, (2007); 85(2): 234–241.
Alzahrani FA, El-Magd MA, Abdelfattah-Hassan A, Saleh AA, Saadeldin IM, et al. Potential Effect of Exosomes Derived from Cancer Stem Cells and MSCs on Progression of DEN-Induced HCC in Rats. Stem Cells Int. (2018 ); 27; 8058979.
Peng L, Xie DY, Lin BL, Liu J, Zhu HP, et al. Autologous bone marrow mesenchymal stem cell transplantation in liver failure patients caused by hepatitis B: short-term and long-term outcomes. Hepatology, (2011); 54 (3): 820-828.
Lanthier N, Lin-Marq N, Rubbia-Brandt L, Clement S, Goossens N, Spahr L. Autologous bone marrow derived cell transplantation in decompensated alcoholic liver disease: What is the impact on liver histology and gene expression patterns? Stem Cell Research & Therapy, (2017); 8(1): 1-10.
Cao Q, Batey R, Pang G, Russell A, Clancy R. IL‐6, IFN‐γ and TNF‐α production by liver‐associated T cells and acute liver injury in rats administered concanavalin A. Immunology and cell biology, (1998); 76(6): 542-549.
Cho K, Woo S, Seoh J, Han H, Ryu K. Mesenchymal stem cells restore CCl4‐induced liver injury by antioxidative process. Cell Biology International, (2012); 36(12): 1267–1274.
Suk KT, Yoon JH, Kim MY, Kim CW, Kim JK, et al. Transplantation with autologous bone marrow‐derived mesenchymal stem cells for alcoholic cirrhosis: Phase 2 trial. Hepatology, (2016); 64(6): 2185-2197.
Rani R, Tandon A, Wang J, Kumar S, Gandhi CR. Stellate Cells Orchestrate Concanavalin A–Induced Acute Liver Damage. The American Journal of Pathology, (2017); 187(9): 2008–2019.
khaleel A, El-Sheakh AR, Suddek GM. Celecoxib abrogates concanavalin a-induced hepatitis in mice: Possible involvement of Nrf2/HO-1, JNK signaling pathways and COX-2 expression. International Immunopharmacology, (2023); 121: 110442.
Chen L, Zhang C, Chen L, Wang X, Xiang B, et al. Human Menstrual Blood-Derived Stem Cells Ameliorate Liver Fibrosis in Mice by Targeting Hepatic Stellate Cells via Paracrine Mediators. Stem Cells Translational Medicine, (2016); 6(1): 272–284.
Chi G, Pei J, Li X. The imbalance of liver resident macrophages polarization promotes chronic autoimmune hepatitis development in mice. PeerJ, (2023); 11:e14871.
Kato M. Involvement of IL-10, an anti-inflammatory cytokine in murine liver injury induced by concanavalin a. Hepatology Research, (2001);20(2): 232–243.
Chen L, Xie XJ, Ye YF, Zhou L, Xie HY, et al. Kupffer cells contribute to concanavalin A-induced hepatic injury through a Th1 but not Th17 type response-dependent pathway in mice. Hepatobiliary & Pancreatic Diseases International, (2011); 10(12): 171–178.
Chen Y, Jeffery HC, Hunter S, Bhogal R, Birtwistle J, et al. Human intrahepatic regulatory T cells are functional, require IL‐2 from effector cells for survival, and are susceptible to Fas ligand‐mediated apoptosis. Hepatology, (2016); 64(1): 138–150.
Qu M, Yuan X, Liu D, Ma Y, Zhu J, et al. Bone Marrow-Derived Mesenchymal Stem Cells Attenuate Immune-Mediated Liver Injury and Compromise Virus Control During Acute Hepatitis B Virus Infection in Mice. Stem cells and development, (2017); 26(11):818–827.
Wang H, Zhang H, Huang B, Miao G, Yan X, et al. Mesenchymal stem cells reverse high fat diet induced non alcoholic fatty liver disease through suppression of CD4+ T lymphocytes in mice. Molecular Medicine Reports, (2018); 17(3): 3769-3774.
Caplan AI, Dennis JE. Mesenchymal stem cells as trophic mediators. Journal of Cellular Biochemistry, (2006); 98(5): 1076–1084.
Reger R L, Tucker A, Wolfe MR. Differentiation and characterization of human MSCs. Humana Press eBooks, (2008); 93-107
Kurtz A. Mesenchymal Stem Cell Delivery Routes and Fate. International Journal of Stem Cells, (2008); 1(11): 1–7.
Barbash IM, Chouraqui P, Baron J, Feinberg MS, Etzion S, et al. Systemic Delivery of Bone Marrow–Derived Mesenchymal Stem Cells to the Infarcted Myocardium. Circulation, (2003); 108 (7): 863–868.
Ortiz LA, Gambelli F, McBride C, Gaupp D, Baddoo M, et al. Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects. Proceedings of the National Academy of Sciences, (2003); 100 (14): 8407–8411.
Laird DJ, von Andrian UH, Wagers AJ. Stem cell trafficking in tissue development, growth, and disease. Cell, (2008); 132(4): 612-630.
Chen Y, Xiang LX, Shao JZ, Pan RL, Wang YX, et al. Recruitment of endogenous bone marrow mesenchymal stem cells towards injured liver. Journal of Cellular and Molecular Medicine, (2009); 14(6b): 1494–1508.
DOI: http://dx.doi.org/10.62940/als.v12i1.3171
Refbacks
- There are currently no refbacks.